Literatur
-
1
Hoofnagle J H.
Hepatitis C: the clinical spectrum of disease.
Hepatology.
1997;
26 (Suppl. 1)
15S-20S (Übersicht)
-
2
Seeff L B.
Natural history of hepatitis C.
Hepatology.
1997;
26 (Suppl. 1)
21S (Übersicht)
-
3
Poynard T, Bedossa P, Opolon P.
Natural history of liver fibrosis progression in patients with chronic hepatitis C.
Lancet.
1997;
349
825-832 (III)
-
4
Rockstroh J K, Woiotas R P, Spengler U.
Human immunodeficiency virus and hepatitis C virus coinfection.
Eur J Med Res.
1998;
3
269-277 (Übersicht)
-
5
Di Bisceglie A H.
Hepatitis C and hepatocellular carcinoma.
Hepatology.
1997;
26 (Suppl. 1)
34S (Übersicht)
-
6
Hsukuma H, Hiyama T, Tanaka. et al .
Risk factors for hapatocellular carcinoma among patients with chronic liver disease.
N Engl J Med.
1993;
328
1797-1801 (III)
-
7
Pessione F, Degos F, Marcellin P. et al .
Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.
Hepatology.
1998;
27
1717-1722 (III)
-
8
Eyster M E, Diamondstone L S, Lien J M. et al .
Natural history of hepatitis C virus in multitransfused hemophiliacs: effect of co-infection with human immunodeficiency virus. The multicenter hemophilia cohort study.
J Acquir Immune Defic Syndr.
1993;
6
602-610 (III)
-
9
Weltman M, Brotodihardjo A, Crewe E. et al .
Coinfection with hepatitis B and C, C and D viruses results in severe chronic liver disease and responds poorly to interferon-treatment.
J Viral Hepatitis.
1995;
2
39-45 (III)
-
10
Perillo R P.
The role of liver biopsy in Hepatitis C.
Hepatology.
1997;
26 (Suppl. 1)
57-61 (III)
-
11
Liang T J, Rehermann B, Seef L B. et al .
Pathogenesis, natural history, treatment, and prevention of hepatitis C. NIH Conference.
Ann Intern Med.
2000;
132
296-305 (III)
-
12
Niederau C, Lange S, Heintges T. et al .
Prognosis of chronic hepatitis C: results of a large, prospective cohort study.
Hepatology.
1998;
28
1687-1695 (III)
-
13
Mathurin P, Moussalli J, Cadranal J F. et al .
Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.
Hepatology.
1998;
27
868-872 (IIa)
-
14
Ohata K, Hamasaki K, Toriyama K. et al .
Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
Cancer.
2003;
97
3036-3034 (IV)
-
15
El-Serag H B, Mason A C.
Rising incidence of hepatocellular carcinoma in the United states.
N Engl J Med.
1999;
340
745-750 (III)
-
16
Alter M J.
Epidemiology of hepatitis C.
Hepatology.
1997;
26
62S-65S (Übersicht)
-
17
Eyster M E, Alter H J, Aledort L M. et al .
Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Ann Inern Med.
1991;
115
764-768 (IV)
-
18
Schreiber G B, Busch M P, Kleinmann S H. et al .
The risk of transfusion-transmitted viral infection.
N Engl J Med.
1996;
334
1685-1690 (III)
-
19
Everhart J E, Di Bisceglie A M, Murray L M. et al .
Risk for non-A, non-B (type C) hepatitis through sexual and household contact with chronic carriers.
Ann Intern Med.
1990;
112
544-555 (III)
-
20
Dienstag J L.
Sexual and perinatal transmission of hepatitis C.
Hepatology.
1997;
26 (Suppl. 1)
665-705 (III)
-
21
Neumayr G, Probst A, Schwaighofer H. et al .
Lack of evidence for sexual transmission of hepatitis C.
QJM Sep.
1999;
92
505-508 (III)
-
22
Meisel H, Reip A, Faltus B. et al .
Transmission of hepatitis C virus to children and husbands by woman infected with contaminated anti-D immunoglobulin.
Lancet.
1995;
345
1209-1211 (III)
-
23
Thomas D L, Zenilman J M, Alter H J. et al .
Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - analysis of 309 sex partnerships.
J Infect Dis.
1995;
171
768-775 (III)
-
24
Hon C H, Chen W V, Kao D S.
Intrafamilial transmission of hepatitis C virus in hemodialysis patients.
J Med Virol.
1995;
45
381-385 (III)
-
25
Tokars J I, Miller E R, Alter M J. et al .
National surveillance of dialysis associated diseases in the United States 1995.
ASAIO J.
1998;
44
98-107 (IV)
-
26
Caramelo C, Navas S, Alberola M L.
Evidence against transmission of hepatitis C virus through hemodialysis ultrafiltrate and peritoneal fluid.
Nephron.
1994;
66
470-473 (III)
-
27
Terekerz P M, Pearson R, Jagger J.
Infected physicans and invasive procedures: national policy and legal reality.
Milbank Q.
1999;
77
511-529 (IV)
-
28
Haley R W, Fischer R P.
Commercial tattoing as a potential important source of hepatitis C infection.
Medicine.
2001;
80
134-151 (III)
-
29
Enders G, Braun R.
Prä- und perinatale Übertragung des Hepatitis C Virus.
Internist.
2000;
7
676-678 (III)
-
30
Johnson R J, Gretch D R, Couser W G. et al .
Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy.
Kidney Int.
1994;
46
1700-1704 (IIb)
-
31
Zuckerman E, Keren D, Rozenbaum M. et al .
Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha.
Clin Exp Rheumatol.
2000;
18
579-584 (IIb)
-
32
Misiani R, Bellavita P, Fenili D. et al .
Interferon alpha-2 a therapy in cryoglobulinemia associated with hepatitis c virus.
N Engl J Med.
1994;
330
751-756 (Ib)
-
33
Zuckermann E, Keren D, Slobodin G. et al .
Treatment of refractory, sympotmatic, hepatitis c virus-related mixed cryoglobulinemia with ribavirin and interferon alpha.
J Rheumatol.
2000;
27
2172-2178 (IIb)
-
34
Foster G R, Goldin R D, Thomas H C.
Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis.
Hepatology.
1998;
27
209-212 (III)
-
35
Okuda K.
Hepatocellular carcinoma.
J Hepatol.
2000;
32
225-237 (Übersicht)
-
36
Niederau C, Lange S, Heintges T. et al .
Prognosis of chronic hepatitis C: results of a large, prospective cohort study.
Hepatology.
1998;
28
1687-1695 (III)
-
37
Poynard T, Marcellin P, Lee S S. et al .
Randomized trial of interferon alpha 2 b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2 b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.
Lancet.
1998;
352
1426-1432 (Ib)
-
38
Poynard T, McHutchinson J, Gopodmann Z. et al .
Is an „A la carte” combination interferon alpha 2 b regime possible for the first line treatment in patients with chronic hepatitis C.
Hepatology.
2000;
31
211-217 (III)
-
39
Manns M P, McHutchinson J G, Gordon S. et al .
Peginterferon alfa 2 b plus ribavirin compared to interferon alfa 2 b plus ribavirin for treatment of chronic hepatitis C: a randomized trial.
Lancet.
2001;
358
958-965 (Ib)
-
40
Meisel H, Reip A, Faltus B. et al .
Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunglobulin.
Lancet.
1995;
345
1209-1211 (III)
-
41
Vogt M, Lang T, Frosner G. et al .
Prevalence and clinical outcome of hepatitis C infection in children whounderwent cardiac surgery before the implementation of blood-donor screening.
N Engl J Med.
1999;
341
866-870 (III)
-
42
Jonas M M, Ott M J, Nelson S P. et al .
Interferon-α treatment of chronic hepatitis C virus infection in children.
Pediatr Infect Dis J.
1998;
17
241-246 (IIb)
-
43
Boyer N, Marcellin P, Degott C. et al .
Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comite des Anti-Viraux.
J Infect Dis.
1992;
165
723-726 (III)
-
44
Causse X, Payen J L, Izopet J. et al .
Does HIV-Infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group.
J Hepatol.
2000;
32
1003-1010 (III)
-
45
Zylberberg H, Benhamou Y, Lagneaux J L. et al .
Safety and efficiacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
GUT.
2000;
47
694-697 (III)
-
46
Jannssen H L, Brouwer J T, van der Mast R C. et al .
Suicide associated with alfa-interferon therapy for chronic viral hepatitis.
J Hepatol.
1994;
21
241-243 (IV)
-
47
Heathcote E J, Shiffman M L, Cooksley W G. et al .
Peginterferon alfa-2 a in patients with chronic hepatitis C and cirrhosis.
N Engl J Med.
2000;
343
1673-1680 (Ib)
-
48
Persico M, Persico E, Suozzo R. et al .
Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.
Gastroenterology.
2000;
118
760-764 (III)
-
49
Puoti C, Magrini A, Stati T. et al .
Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels.
Hepatology.
1997;
26
1393-1398 (III)
-
50
Jaeckel E, Manns M P.
The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible?.
Z Gastroenterol.
2000;
38
387-395 (Übersicht)
-
51
Jaeckel E, Cornberg M, Wedemeyer H. et al .
German Acute Hepatitis C Therapy Group: Treatment of acute hepatitis C with interferon alfa-2 b.
N Engl J Med.
2001;
345
1452-1457 (IIb)
Prof. Dr. med. W. E. Fleig
Universitätsklinik und Poliklinik für Innere Medizin I, Martin-Luther-Universität Halle-Wittenberg
Ernst-Grube-Straße 40
06120 Halle
